Please ensure Javascript is enabled for purposes of website accessibility

Here's Why LivaNova Dropped Today

By Brian Orelli, PhD - Nov 20, 2018 at 1:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Centers for Medicare and Medicaid Services wants some more data before covering the company’s depression therapy.

What happened

Shares of LivaNova (LIVN 0.87%) were down 14.7% at 11:52 a.m. EST after the Centers for Medicare and Medicaid Services (CMS) issued a proposed decision memo over coverage for its Vagus Nerve Stimulation (VNS) therapy system for treatment-resistant depression.

So what

CMS doesn't currently cover LivaNova's VNS therapy, but agreed to review its coverage decision earlier this year based on evidence that VNS therapy is helping patients with treatment-resistant depression, especially in Europe.

Unfortunately for LivaNova, rather than reversing its policy and covering VNS therapy, CMS took a middle-ground approach, proposing that the company run a placebo-controlled clinical trial following patients for at least a year, which -- if it yields positive results -- could lead to CMS covering the medical device.

LivaNova estimates there's a lot of pent-up demand from patients in the government programs, so the decision not to cover the therapy immediately is clearly a big lost opportunity. On the bright side, CMS' proposed decision puts LivaNova a step closer to getting coverage eventually, albeit a few years from now.

Man with eyes closed holding his head

Image source: Getty Images.

Now what

As the government is apt to do, CMS will take comments on its proposal before issuing a final decision. But investors should keep in mind that the agency already took comments before issuing this proposal, so it's unlikely that the proposal will change much.

A final ruling from CMS is expected on or before Feb. 17, 2019, at which point LivaNova can get started on setting up a clinical trial to prove its VNS therapy is worthy of CMS coverage.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

LivaNova PLC Stock Quote
LivaNova PLC
LIVN
$65.01 (0.87%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.